BioSpace News Archive

Emergent BioSolutions Inc. today announced that its Board of Directors has appointed Joseph C. Papa as president and CEO, effective February 21, 2024.

Verge Genomics announced today that Verge Co-founder and CEO Alice Zhang will present at the virtual Evercore ISI 2024 Emerging Biotech Conference, on Wednesday, February 28th from 10:45 a.m. – 11:15 a.m. EST.

Nanoscope Therapeutics Inc. today announced that Sulagna Bhattacharya , Chief Executive Officer of Nanoscope Therapeutics, and other members of its senior management team will participate in two upcoming conferences.

REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Tuesday, February 27, 2024, at 4:30 p.m. ET to discuss its financial results for the fourth quarter and full year ended December 31, 2023, and recent operational highlights.

Revvity, Inc. (NYSE: RVTY) today announced it will present at the following investor conferences in February and March 2024.

Charles River Laboratories International, Inc. (NYSE: CRL) today announced a strategic agreement with Wheeler Bio, Inc., an antibody contract development and manufacturing organization (CDMO) focused on preclinical and early clinical supply of recombinant proteins, providing clients access to Wheeler’s Portable CMC® (Chemistry, Manufacturing and Controls) platform.

Revance Therapeutics, Inc. announced that the company will be participating in the following investor conferences.

KaliVir Immunotherapeutics, Inc. today announced the appointment of industry leader James M. Burke, M.D., as Chief Medical Officer (CMO) to further advance its vision of providing patients with truly life changing cancer therapeutics by leveraging its next generation oncolytic virus platform.

Tenon Medical, Inc. (“Tenon” or the “Company”) (NASDAQ:TNON) today announced the closing of a private placement of 172,239 shares of the Company’s Series A Preferred Stock (the “Preferred Stock”) and 258,374 warrants to purchase the Company’s common stock at an exercise price of $1.27 per share at a combined offering price of $15.125 per share of Preferred Stock, for total gross proceeds of approximately $2.6 million.

DNAnexus, Inc. and Curio Bioscience today announced a collaboration to streamline and simplify data analysis for high-resolution, whole transcriptome spatial mapping studies.